Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 0 | $0 |
| Sells | 25 | $18,680,848 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 200 | 248.58 | 49,716 | D |
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 407 | 247.7582 | 100,838 | D |
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 600 | 246.9773 | 148,186 | D |
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 945 | 244.7881 | 231,325 | D |
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 300 | 245.6867 | 73,706 | D |
| 10 Apr 2024 20:53 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 08 Apr 2024 | Sale | 224 | 243.245 | 54,487 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 5,278 | 245.5332 | 1,295,924 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 2,079 | 244.4509 | 508,213 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 8,817 | 242.6073 | 2,139,069 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 8,989 | 243.3294 | 2,187,288 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 700 | 241.1413 | 168,799 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 05 Apr 2024 | Sale | 1,643 | 240.1076 | 394,497 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 100 | 248.23 | 24,823 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 711 | 247.2268 | 175,778 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 1,653 | 246.0123 | 406,658 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 435 | 244.0066 | 106,143 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 2,734 | 245.0643 | 670,006 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 3,085 | 242.7114 | 748,765 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 5,619 | 241.8528 | 1,358,971 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 04 Apr 2024 | Sale | 4,200 | 240.8759 | 1,011,679 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 03 Apr 2024 | Sale | 2,089 | 246.3249 | 514,573 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 03 Apr 2024 | Sale | 18,917 | 245.3356 | 4,641,014 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 03 Apr 2024 | Sale | 4,070 | 244.6815 | 995,854 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 03 Apr 2024 | Sale | 2,634 | 243.6849 | 641,866 | D |
| 05 Apr 2024 20:50 | MDGL | MADRIGAL PHARMACEUTICALS Inc | TAUB REBECCA | Pres., R&D, and CMO | 03 Apr 2024 | Sale | 135 | 242 | 32,670 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)